SYRS News and Press, Syros Pharmaceuticals Inc. From 11/04/21

AMCX,AMR,AXL,BBU,BEP,CGAU,CGC,CLMT,CNK,CNTY,D,DKNG,DOC,DTM,EAF,ELAN,ENB,EOG,ERJ,ESNT,FLR,GCI,OTCPK:GCTAF,GECC,GLP,GOOS,GRPN,GT,HE,HMC,INTT,JCI,KIM,LMRK,MFA,MGA,MITT,NMRK,NOG,NWN,OFS,ONCY,PLYM,PNW,REV,SII,SRE,SSP,SYRS,TEN,TRP,TU,TUSK,VRS,VST,VTR,XELA For Seeking Alpha's full earnings season ca...

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q3 earnings results on Friday, November 5th, before market open. The consensus EPS Estimate is -$0.44 (-2.3% Y/Y) and the consensus Revenue Estimate is $4.48M (+17.9% Y/Y). Over the last 2 years, SYRS has beaten EPS estimates 75% of...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and pro...

Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Company’s recently hired Chief Financial Officer, in ac...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experie...

Confirmatory Dose and PK Data Expected in First Half of 2022, with a Phase 3 Trial Expected to Begin in 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been do...

Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Conley Chee, the Company’s recently hired Chief Commercial Officer, in ...

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with this event. For further details see: Syros Pharmaceuticals (SYRS) Investor Presentation

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketi...

Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer in 4Q 2021 Plan to Initiate Phase 1b Trial Evaluat...